122 related articles for article (PubMed ID: 37839045)
21. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.
Kote-Jarai Z; Amin Al Olama A; Leongamornlert D; Tymrakiewicz M; Saunders E; Guy M; Giles GG; Severi G; Southey M; Hopper JL; Sit KC; Harris JM; Batra J; Spurdle AB; Clements JA; Hamdy F; Neal D; Donovan J; Muir K; Pharoah PD; Chanock SJ; Brown N; Benlloch S; Castro E; Mahmud N; O'Brien L; Hall A; Sawyer E; Wilkinson R; Easton DF; Eeles RA
Hum Genet; 2011 Jun; 129(6):687-94. PubMed ID: 21465221
[TBL] [Abstract][Full Text] [Related]
22. HNF1B polymorphism associated with development of prostate cancer in Korean patients.
Kim HJ; Bae JS; Lee J; Chang IH; Kim KD; Shin HD; Han JH; Lee SY; Kim W; Myung SC
Urology; 2011 Oct; 78(4):969.e1-6. PubMed ID: 21982019
[TBL] [Abstract][Full Text] [Related]
23. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
[TBL] [Abstract][Full Text] [Related]
24. Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population.
Kotarac N; Dobrijevic Z; Matijasevic S; Savic-Pavicevic D; Brajuskovic G
Pathol Oncol Res; 2020 Oct; 26(4):2409-2423. PubMed ID: 32556890
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Shui IM; Lindström S; Kibel AS; Berndt SI; Campa D; Gerke T; Penney KL; Albanes D; Berg C; Bueno-de-Mesquita HB; Chanock S; Crawford ED; Diver WR; Gapstur SM; Gaziano JM; Giles GG; Henderson B; Hoover R; Johansson M; Le Marchand L; Ma J; Navarro C; Overvad K; Schumacher FR; Severi G; Siddiq A; Stampfer M; Stevens VL; Travis RC; Trichopoulos D; Vineis P; Mucci LA; Yeager M; Giovannucci E; Kraft P
Eur Urol; 2014 Jun; 65(6):1069-75. PubMed ID: 24411283
[TBL] [Abstract][Full Text] [Related]
26. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
[TBL] [Abstract][Full Text] [Related]
27. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
[TBL] [Abstract][Full Text] [Related]
28. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.
Chen YC; Giovannucci E; Kraft P; J Hunter D
Carcinogenesis; 2008 May; 29(5):999-1004. PubMed ID: 18375959
[TBL] [Abstract][Full Text] [Related]
29. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India.
Mandal RK; Gangwar R; Mandhani A; Mittal RD
DNA Cell Biol; 2010 Apr; 29(4):183-90. PubMed ID: 20070155
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of genetic biomarkers in clinical progression of prostate cancer.
Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Saiz M; Carmona-Saez P; Alvarez JC; Pascual-Geler M; Lorente JA; Cozar JM
Exp Mol Med; 2015 Aug; 47(8):e176. PubMed ID: 26251261
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis.
Zambon CF; Prayer-Galetti T; Basso D; Padoan A; Rossi E; Secco S; Pelloso M; Fogar P; Navaglia F; Moz S; Zattoni F; Plebani M
J Urol; 2012 Oct; 188(4):1124-30. PubMed ID: 22901566
[TBL] [Abstract][Full Text] [Related]
32. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.
Yokomizo A; Koga H; Kinukawa N; Tsukamoto T; Hirao Y; Akaza H; Mori M; Naito S
Prostate; 2004 Nov; 61(3):248-52. PubMed ID: 15368467
[TBL] [Abstract][Full Text] [Related]
33. Genetic variants in RNA-induced silencing complex genes and prostate cancer.
Nikolić Z; Savić Pavićević D; Vučić N; Cerović S; Vukotić V; Brajušković G
World J Urol; 2017 Apr; 35(4):613-624. PubMed ID: 27498138
[TBL] [Abstract][Full Text] [Related]
34. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer.
Onen IH; Ekmekci A; Eroglu M; Konac E; Yesil S; Biri H
Exp Biol Med (Maywood); 2008 Dec; 233(12):1608-14. PubMed ID: 18849534
[TBL] [Abstract][Full Text] [Related]
35. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
37. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
38. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
Urologiia; 2015; (5):46-50. PubMed ID: 26859937
[TBL] [Abstract][Full Text] [Related]
39. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
40. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
